UroGen Pharma (NASDAQ:URGN) PT Lowered to $32.00 at Oppenhei

UroGen Pharma (NASDAQ:URGN – Free Report) had its price target cut by Oppenheimer from $34.00 to $32.00 in a research report sent to investors on Tuesday, Benzinga reports. They currently have an outperform rating on the stock. Separately, HC Wainwright reaffirmed a buy rating and set a $54.00 target price on shares of UroGen Pharma […]

Related Keywords

China , Urogen Pharma , Mark Schoenberg , Urogen Pharma Ltd , Nasdaq , Connor Clark Lunn Investment Management Ltd , China Universal Asset Management Co , Allspring Global Investments Holdings , Jump Financial , Securities Exchange Commission , Free Report , Gen Pharma Trading Down , Gen Pharma , Get Free Report , Exchange Commission , Global Investments Holdings , Universal Asset Management , Financial Markets , Connor Clark , Lunn Investment Management , Gen Pharma Ltd , Urogen Pharma Daily ,